Differently, lobular breast carcinomas usually show absence of Her-2/neu and topoisomerase-IIα gene amplification (according to both FDA or ASCO/CAP cut-offs[11]), thus patients constantly lack the ad hoc predictive rationale for receiving common chemotherapy that includes anthracyclines; in addition, invasive lobular carcinomas commonly underexpress Her-2 showing lack of tailored scheme of therapies. This evidence concerns the gene ERBB2 and breast lobular carcinoma.